NYSEAMERICAN:XXII - 22nd Century Group Stock Price, Price Target & More

$2.22 -0.09 (-3.90 %)
(As of 04/23/2018 01:39 AM ET)
Previous Close$2.22
Today's Range$2.2050 - $2.3101
52-Week Range$1.13 - $4.44
Volume1.27 million shs
Average Volume3.47 million shs
Market Capitalization$316.82 million
P/E RatioN/A
Dividend YieldN/A
Beta3.25

About 22nd Century Group (NYSEAMERICAN:XXII)

22nd Century Group logo22nd Century Group, Inc., a plant biotechnology company, provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding. It develops smoking cessation products and modified risk tobacco products for smokers who are unable or unwilling to quit smoking and who may be interested in cigarettes, which reduce exposure to nicotine or to certain tobacco smoke toxins and/or pose a lower health risk than conventional cigarettes. The company's products include RED SUN and MAGIC regular and menthol cigarettes; and SPECTRUM government research cigarettes. It is also developing X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation; and modified risk cigarettes, such as BRAND A, which has approximately 95% less nicotine than conventional tobacco cigarettes, as well as BRAND B cigarettes that contain low amount of tar per milligram of nicotine. 22nd Century Group, Inc. has a scientific collaboration with the University of Virginia; and a strategic partnership with Anandia Laboratories, Inc. The company was founded in 1998 and is headquartered in Clarence, New York.

Receive XXII News and Ratings via Email

Sign-up to receive the latest news and ratings for XXII and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryCannabis
SectorMedical
SymbolNYSEAMERICAN:XXII
CUSIPN/A
Phone+1-716-2701523

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-73.20%
Return on Equity-50.30%
Return on Assets-43.77%

Miscellaneous

EmployeesN/A
Outstanding Shares124,140,000

How to Become a New Pot Stock Millionaire

22nd Century Group (NYSEAMERICAN:XXII) Frequently Asked Questions

What is 22nd Century Group's stock symbol?

22nd Century Group trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XXII."

How were 22nd Century Group's earnings last quarter?

22nd Century Group (NYSEAMERICAN:XXII) announced its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.01. The biotechnology company earned $4.53 million during the quarter, compared to analyst estimates of $5.09 million. 22nd Century Group had a negative net margin of 73.20% and a negative return on equity of 50.30%. The company's revenue was up 46.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.03) earnings per share. View 22nd Century Group's Earnings History.

What price target have analysts set for XXII?

1 brokerages have issued 1 year price targets for 22nd Century Group's stock. Their predictions range from $11.50 to $11.50. On average, they expect 22nd Century Group's share price to reach $11.50 in the next twelve months. View Analyst Ratings for 22nd Century Group.

Are investors shorting 22nd Century Group?

22nd Century Group saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 12,167,542 shares, an increase of 10.3% from the March 15th total of 11,036,154 shares. Based on an average daily volume of 2,809,792 shares, the short-interest ratio is currently 4.3 days. Currently, 11.2% of the shares of the stock are sold short.

Who are some of 22nd Century Group's key competitors?

Who are 22nd Century Group's key executives?

22nd Century Group's management team includes the folowing people:
  • Mr. Henry Sicignano III, MBA, Chief Exec. Officer, Pres and Director (Age 50)
  • Mr. John T. Brodfuehrer, Chief Financial Officer and Treasurer (Age 60)
  • Mr. Thomas L. James Esq., VP, Gen. Counsel and Sec. (Age 59)
  • Dr. Paul J. Rushton Ph.D., VP of Plant Biotechnology (Age 55)
  • James Vail, Director of Communications

Has 22nd Century Group been receiving favorable news coverage?

Media headlines about XXII stock have trended somewhat positive on Monday, Accern reports. Accern rates the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. 22nd Century Group earned a coverage optimism score of 0.05 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.85 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of 22nd Century Group?

Shares of XXII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is 22nd Century Group's stock price today?

One share of XXII stock can currently be purchased for approximately $2.22.

How big of a company is 22nd Century Group?

22nd Century Group has a market capitalization of $316.82 million.

How can I contact 22nd Century Group?

22nd Century Group's mailing address is 9530 Main St, CLARENCE, NY 14031-1915, United States. The biotechnology company can be reached via phone at +1-716-2701523.


MarketBeat Community Rating for 22nd Century Group (XXII)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  289
MarketBeat's community ratings are surveys of what our community members think about 22nd Century Group and other stocks. Vote "Outperform" if you believe XXII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XXII will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

22nd Century Group (NYSEAMERICAN:XXII) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for 22nd Century Group in the last 12 months. Their average twelve-month price target is $11.50, suggesting that the stock has a possible upside of 418.02%. The high price target for XXII is $11.50 and the low price target for XXII is $11.50. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.50$11.50$11.50$11.50
Price Target Upside: 418.02% upside197.16% upside1,110.53% upside1,110.53% upside

22nd Century Group (NYSEAMERICAN:XXII) Consensus Price Target History

Price Target History for 22nd Century Group (NYSEAMERICAN:XXII)

22nd Century Group (NYSEAMERICAN:XXII) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
1/26/2018Chardan CapitalReiterated RatingBuy -> Buy$11.50View Rating Details
(Data available from 4/23/2016 forward)

Earnings

22nd Century Group (NYSEAMERICAN:XXII) Earnings History and Estimates Chart

Earnings by Quarter for 22nd Century Group (NYSEAMERICAN:XXII)

22nd Century Group (NYSEAMERICAN XXII) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.02)($0.03)$5.09 million$4.53 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.04)$3.90 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.03)$2.23 millionViewN/AView Earnings Details
3/8/2017Q4 2016($0.03)$3.34 millionViewN/AView Earnings Details
11/8/2016Q3 2016($0.03)$3.10 millionViewN/AView Earnings Details
8/9/2016Q2 2016($0.04)$2.83 millionViewN/AView Earnings Details
5/10/2016Q1($0.03)($0.04)$3.02 millionViewN/AView Earnings Details
2/18/2016Q4 2015($0.04)$2.93 millionViewN/AView Earnings Details
11/9/2015Q3($0.03)($0.04)$2.67 millionViewN/AView Earnings Details
8/4/2015Q215($0.02)($0.02)$1.30 million$2.31 millionViewN/AView Earnings Details
5/11/2015Q1 2015($0.06)$0.62 millionViewN/AView Earnings Details
2/6/2015($0.03)($0.09)ViewN/AView Earnings Details
11/14/2014Q314($0.03)($0.05)$0.06 millionViewN/AView Earnings Details
8/14/2014($0.03)($0.03)$0.02 millionViewN/AView Earnings Details
5/2/2014($0.03)($0.09)$0.45 millionViewN/AView Earnings Details
1/30/2014Q4($0.16)$7.23 millionViewN/AView Earnings Details
11/12/2013Q3 2013($0.32)$0.05 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.01)ViewN/AView Earnings Details
5/16/2012Q1 2012($0.03)ViewN/AView Earnings Details
11/14/2011Q3 2011($0.03)($0.03)ViewN/AView Earnings Details
8/15/2011Q2 2011($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

22nd Century Group (NYSEAMERICAN:XXII) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

22nd Century Group (NYSEAMERICAN XXII) Insider Trading and Institutional Ownership History

Insider Trading History for 22nd Century Group (NYSEAMERICAN:XXII)
Institutional Ownership by Quarter for 22nd Century Group (NYSEAMERICAN:XXII)

22nd Century Group (NYSEAMERICAN XXII) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/29/2017Michael Robert MoynihanVPSell50,000$2.67$133,500.00867,220View SEC Filing  
7/31/2017Michael Robert MoynihanVPSell29,532$2.00$59,064.00917,220View SEC Filing  
6/8/2017Michael Robert MoynihanVPSell20,468$2.00$40,936.00946,752View SEC Filing  
10/31/2016Michael Robert MoynihanVPSell100,000$1.28$128,000.00888,934View SEC Filing  
3/29/2016John T BrodfuehrerCFOBuy12,500$0.77$9,625.00262,500View SEC Filing  
11/3/2015Michael Robert MoynihanVPSell50,000$1.40$70,000.00988,934View SEC Filing  
6/30/2015Joseph PandolfinoDirectorSell91,178$0.95$86,619.10View SEC Filing  
12/31/2014Joseph PandolfinoDirectorSell105,124$1.65$173,454.60View SEC Filing  
12/26/2014Joseph PandolfinoDirectorSell41,722$1.54$64,251.88View SEC Filing  
12/22/2014Joseph PandolfinoDirectorSell52,683$1.60$84,292.80View SEC Filing  
12/17/2014Joseph PandolfinoDirectorSell75,768$1.62$122,744.16View SEC Filing  
12/11/2014Joseph PandolfinoDirectorSell67,836$1.65$111,929.40View SEC Filing  
5/9/2014Richard M SandersDirectorBuy20,000$2.23$44,600.00View SEC Filing  
4/23/2014Michael Robert MoynihanVPSell100,000$2.44$244,000.00View SEC Filing  
3/12/2014Joseph PandolfinoCEOSell95,000$5.73$544,350.00View SEC Filing  
12/10/2013Clearwater Partners, LlcMajor ShareholderSell10,000$1.55$15,500.00View SEC Filing  
12/3/2013Clearwater Partners, LlcMajor ShareholderSell10,000$1.35$13,500.00View SEC Filing  
11/19/2013Clearwater Partners, LlcMajor ShareholderSell30,074$1.09$32,780.66View SEC Filing  
11/13/2013Clearwater Partners, LlcMajor ShareholderSell11,826$0.98$11,589.48View SEC Filing  
11/11/2013Clearwater Partners, LlcMajor ShareholderSell7,100$1.03$7,313.00View SEC Filing  
11/7/2013Clearwater Partners, LlcMajor ShareholderSell9,000$1.15$10,350.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

22nd Century Group (NYSEAMERICAN XXII) News Headlines

Source:
DateHeadline
Better Marijuana Stock: 22nd Century Group vs. Insys PharmaceuticalsBetter Marijuana Stock: 22nd Century Group vs. Insys Pharmaceuticals
finance.yahoo.com - April 14 at 5:50 PM
22nd Century Group (XXII) Sees Significant Increase in Short Interest22nd Century Group (XXII) Sees Significant Increase in Short Interest
www.americanbankingnews.com - April 10 at 6:56 PM
22nd Century Group (XXII) Given New $11.50 Price Target at Chardan Capital22nd Century Group (XXII) Given New $11.50 Price Target at Chardan Capital
www.americanbankingnews.com - April 7 at 9:11 AM
22nd Century Group Inc (XXII) Short Interest Up 9.0% in March22nd Century Group Inc (XXII) Short Interest Up 9.0% in March
www.americanbankingnews.com - March 26 at 6:32 PM
22nd Century Group (XXII) Announces Advance FDA Notice of Proposed Rulemaking on Lowering Nicotine in Cigarettes - StreetInsider.com22nd Century Group (XXII) Announces Advance FDA Notice of Proposed Rulemaking on Lowering Nicotine in Cigarettes - StreetInsider.com
www.streetinsider.com - March 20 at 3:27 PM
4 Stocks To Watch Following The FDAs Proposal To Lower Nicotine In Cigarettes - Benzinga4 Stocks To Watch Following The FDA's Proposal To Lower Nicotine In Cigarettes - Benzinga
www.benzinga.com - March 19 at 3:22 PM
FDA Publishes Advance Notice of Proposed Rulemaking (ANPRM) on Lowering Nicotine in Cigarettes - Business Wire (press release)FDA Publishes Advance Notice of Proposed Rulemaking (ANPRM) on Lowering Nicotine in Cigarettes - Business Wire (press release)
www.businesswire.com - March 19 at 3:22 PM
Why Isn't This Marijuana Stock Booming? (Hint: The Answer Has Nothing to Do With Weed)Why Isn't This Marijuana Stock Booming? (Hint: The Answer Has Nothing to Do With Weed)
finance.yahoo.com - March 19 at 3:22 PM
FDA Publishes Advance Notice of Proposed Rulemaking (ANPRM) on Lowering Nicotine in CigarettesFDA Publishes Advance Notice of Proposed Rulemaking (ANPRM) on Lowering Nicotine in Cigarettes
finance.yahoo.com - March 19 at 3:22 PM
4 Stocks To Watch Following The FDAs Proposal To Lower Nicotine In Cigarettes4 Stocks To Watch Following The FDA's Proposal To Lower Nicotine In Cigarettes
finance.yahoo.com - March 19 at 3:22 PM
Data Shows that the Global Legal Cannabis Market is Set to Increase in Value - PR Newswire (press release)Data Shows that the Global Legal Cannabis Market is Set to Increase in Value - PR Newswire (press release)
www.prnewswire.com - March 13 at 3:24 PM
Technical Perspectives on Biotech Stocks -- 22nd Century, Abeona Therapeutics, Advaxis, and Adverum Biotechnologies - PR Newswire (press release)Technical Perspectives on Biotech Stocks -- 22nd Century, Abeona Therapeutics, Advaxis, and Adverum Biotechnologies - PR Newswire (press release)
www.prnewswire.com - March 12 at 3:17 PM
22nd Century Group Inc (XXII) Short Interest Up 20.7% in February22nd Century Group Inc (XXII) Short Interest Up 20.7% in February
www.americanbankingnews.com - March 9 at 6:02 PM
22nd Century Group Files 2017 Annual Report and Announces ... - Business Wire (press release)22nd Century Group Files 2017 Annual Report and Announces ... - Business Wire (press release)
www.businesswire.com - March 8 at 5:22 AM
Are 22nd Century Group Inc’s (NYSEMKT:XXII) Interest Costs Too High?Are 22nd Century Group Inc’s (NYSEMKT:XXII) Interest Costs Too High?
finance.yahoo.com - March 7 at 3:16 PM
17th World Conference on Tobacco or Health Will Feature ... - Business Wire (press release)17th World Conference on Tobacco or Health Will Feature ... - Business Wire (press release)
www.businesswire.com - March 7 at 5:30 AM
17th World Conference on Tobacco or Health Will Feature Discussion on the FDA’s Plan to Dramatically Reduce Nicotine in Cigarettes17th World Conference on Tobacco or Health Will Feature Discussion on the FDA’s Plan to Dramatically Reduce Nicotine in Cigarettes
finance.yahoo.com - March 6 at 3:13 PM
22nd Century Group Inc (NYSEMKT:XXII): Does -2.91% Earnings Drop In A Year Reflect The Long-Term Trend?22nd Century Group Inc (NYSEMKT:XXII): Does -2.91% Earnings Drop In A Year Reflect The Long-Term Trend?
finance.yahoo.com - March 6 at 3:13 PM
22nd Century Group Inc (XXII) Sees Significant Decline in Short Interest22nd Century Group Inc (XXII) Sees Significant Decline in Short Interest
www.americanbankingnews.com - February 28 at 1:32 AM
22nd Century Group (XXII) to Release Quarterly Earnings on Tuesday22nd Century Group (XXII) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 27 at 2:16 AM
22nd Century Group to Present International Survey Findings at the Society for Research on Nicotine and Tobacco ... - Business Wire (press release)22nd Century Group to Present International Survey Findings at the Society for Research on Nicotine and Tobacco ... - Business Wire (press release)
www.businesswire.com - February 22 at 3:22 PM
Are marijuana stocks heading higher?Are marijuana stocks heading higher?
finance.yahoo.com - February 11 at 3:15 PM
Short Interest in 22nd Century Group Inc (XXII) Drops By 3.5%Short Interest in 22nd Century Group Inc (XXII) Drops By 3.5%
www.americanbankingnews.com - February 9 at 6:34 PM
Hedge The Market With HDGE ETF - Seeking AlphaHedge The Market With HDGE ETF - Seeking Alpha
seekingalpha.com - February 5 at 5:18 AM
22nd Century - Cutting Through The Smoke And Hype - 75% Downside - Seeking Alpha22nd Century - Cutting Through The Smoke And Hype - 75% Downside - Seeking Alpha
seekingalpha.com - February 2 at 3:15 PM
FDA Remains Firmly Committed to Nicotine Reduction in Cigarettes - Business Wire (press release)FDA Remains Firmly Committed to Nicotine Reduction in Cigarettes - Business Wire (press release)
www.businesswire.com - February 1 at 3:12 PM
22nd Century to Present at BIO CEO & Investor Conference - Business Wire (press release)22nd Century to Present at BIO CEO & Investor Conference - Business Wire (press release)
www.businesswire.com - February 1 at 3:12 PM
22nd Century to Present at BIO CEO & Investor Conference22nd Century to Present at BIO CEO & Investor Conference
finance.yahoo.com - February 1 at 3:12 PM
FDA Remains Firmly Committed to Nicotine Reduction in CigarettesFDA Remains Firmly Committed to Nicotine Reduction in Cigarettes
finance.yahoo.com - February 1 at 5:19 AM
22nd Century Groups (XXII) "Buy" Rating Reaffirmed at Chardan Capital22nd Century Group's (XXII) "Buy" Rating Reaffirmed at Chardan Capital
www.americanbankingnews.com - January 26 at 3:48 PM
What To Make Of The FDA Vote That Rocked Philip Morris - BenzingaWhat To Make Of The FDA Vote That Rocked Philip Morris - Benzinga
www.benzinga.com - January 26 at 5:13 AM
22nd Century Group Inc (XXII) Short Interest Update22nd Century Group Inc (XXII) Short Interest Update
www.americanbankingnews.com - January 24 at 5:40 PM
Should you buy stock in Boeing, Halliburton, Netflix, NVIDIA or 22nd Century Group Inc?Should you buy stock in Boeing, Halliburton, Netflix, NVIDIA or 22nd Century Group Inc?
www.prnewswire.com - January 22 at 9:49 AM
FDAs tobacco stance faces test with Philip Morris iQOS device - ReutersFDA's tobacco stance faces test with Philip Morris iQOS device - Reuters
www.reuters.com - January 22 at 6:52 AM
Why This Marijuana Stock Skyrocketed 157% in 2017 - Motley FoolWhy This Marijuana Stock Skyrocketed 157% in 2017 - Motley Fool
www.fool.com - January 11 at 10:56 AM
Legal Cannabis Sales Projected to Rise as Demand and Legalization GrowLegal Cannabis Sales Projected to Rise as Demand and Legalization Grow
www.prnewswire.com - January 4 at 10:27 AM
22nd Century Group Inc (XXII) Short Interest Down 3.7% in December22nd Century Group Inc (XXII) Short Interest Down 3.7% in December
www.americanbankingnews.com - December 28 at 2:09 AM
Zacks Investment Research Lowers 22nd Century Group (XXII) to HoldZacks Investment Research Lowers 22nd Century Group (XXII) to Hold
www.americanbankingnews.com - December 19 at 10:22 AM
22nd Century Group Inc (XXII) Sees Significant Growth in Short Interest22nd Century Group Inc (XXII) Sees Significant Growth in Short Interest
www.americanbankingnews.com - December 11 at 8:36 PM
Technical Perspectives on Protalix BioTherapeutics, 22nd Century, CorMedix, and iBio - PR Newswire (press release)Technical Perspectives on Protalix BioTherapeutics, 22nd Century, CorMedix, and iBio - PR Newswire (press release)
www.prnewswire.com - December 6 at 8:56 AM
Form 8-K 22nd Century Group, Inc. For: Nov 28 - StreetInsider.comForm 8-K 22nd Century Group, Inc. For: Nov 28 - StreetInsider.com
www.streetinsider.com - December 4 at 10:31 AM
22nd Century Ships 2.4 Million SPECTRUM® Cigarettes for the National Institute on Drug Abuse - Business Wire (press release)22nd Century Ships 2.4 Million SPECTRUM® Cigarettes for the National Institute on Drug Abuse - Business Wire (press release)
www.businesswire.com - November 30 at 4:24 PM
22nd Century Ships 2.4 Million SPECTRUM® Cigarettes for the National Institute on Drug Abuse22nd Century Ships 2.4 Million SPECTRUM® Cigarettes for the National Institute on Drug Abuse
finance.yahoo.com - November 30 at 4:24 PM
Anticipating FDAs “Reduced Nicotine Mandate,” 22nd Century Will Discontinue US Sales of RED SUN Brand - Business Wire (press release)Anticipating FDA's “Reduced Nicotine Mandate,” 22nd Century Will Discontinue US Sales of RED SUN Brand - Business Wire (press release)
www.businesswire.com - November 23 at 7:59 AM
SHU Portfolio: 22nd Century Group Could Join The Ranks Of Big Tobacco - Seeking AlphaSHU Portfolio: 22nd Century Group Could Join The Ranks Of Big Tobacco - Seeking Alpha
seekingalpha.com - November 16 at 9:58 AM

SEC Filings

22nd Century Group (NYSEAMERICAN:XXII) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

22nd Century Group (NYSEAMERICAN XXII) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.